MOLECULAR MECHANISMS OF DRUG-RESISTANCE IN TUMORS

被引:75
作者
HARRISON, DJ
机构
[1] CRC Laboratories, Department of Pathology, University Medical School, Edinburgh, EH8 9AG, Teviot Place
关键词
DRUG RESISTANCE; MDR1; CYTOCHROME P450; GLUTATHIONE; TOPOISOMERASE; P53; APOPTOSIS; CANCER CHEMOTHERAPY;
D O I
10.1002/path.1711750103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite advances in the design and use of chemotherapeutic drugs, the majority of human cancers are resistant to therapy at presentation or become resistant after an initial partial response. this suggests that resistance may be inherent in a tumour cell or may evolve under the selection pressure of drug administration. A number of possible molecular explanations for drug resistance exist. There may be exclusion of drug from the cell, failure to activate the prodrug to its active form, increased detoxification, alteration in the drug target, enahanced repair capability of the cell after injury, or failure to engage an appropriate response, leading to apoptosis in the damaged cell. Many of these factors may co-exist in vivo in human tumours; some are a feature of cell lineage whilst others appear de novo during disease progression. Modulation of these mechanisms has been of some value in laboratory studies but widespread clinical application and benefit remain some way off.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 27 条
  • [1] Endicott JA, Ling V, The biochemistry of P‐glycoprotein‐mediated multidrug resistance, Annu Rev Biochem, 58, pp. 137-171, (1989)
  • [2] Gottesman MM, Goldstein LJ, Fojo A, Galski H, Pastan I, Expression of the multidrug resistance gene in human cancer, Molecular Cellular Biology of Multidrug Resistance in Tumor Cells, pp. 291-301, (1991)
  • [3] Ramani P, Dewchand H, Expression of mdr1/P‐glycoprotein and p110 in neuroblastoma, J Pathol, 175, pp. 13-22, (1995)
  • [4] Skovsgaard T, Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells, Cancer Res, 38, pp. 1785-1791, (1978)
  • [5] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res, 41, pp. 1967-1972, (1981)
  • [6] Pearson JW, Fogler WE, Volker J, Et al., Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK‐16 monoclonal antibody, J Natl Cancer Inst, 83, pp. 1386-1391, (1993)
  • [7] Schinkel AH, Smith JJM, Van, Et al., Disruption of the mouse mdr1a P‐glycoprotein gene leads to a deficiency in the blood‐brain barrier and to increased sensitivity to drugs, Call, 77, pp. 491-502, (1994)
  • [8] Krishnamachary N, Center MS, The MRP gene associated with a non‐P glycoprotein multidrug resistance encodes a 190 k Dalton membrane bound glycoprotein, Cancer Res, 53, (1993)
  • [9] Kuss BJ, Deely RG, Cole SPC, Et al., Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications, Lancet, 343, pp. 1531-1534, (1994)
  • [10] Scheper R, Broxtermann HJ, Scheffer GL, Et al., Overexpression of a Mr 110,000 vesicular protein in non‐P‐glycoprotein‐mediated multidrug resistance, Cancer Res, 53, pp. 1475-1479, (1993)